In the past decade, monoclonal antibody therapies targeting specific cellular receptors are having a major impact on treatment of malignancies of hematological origin and solid tumors. Monoclonal antibody therapies that target molecules that are also are present on red blood cells and platelets cause interference in routine blood bank pre-transfusion testing. These drugs include anti-CD38, approved for treatment of multiple myeloma but now used for a number of other malignancies and immune complications, anti-CD47 and CD47-related drugs in clinical trials for treatment of hematologic or solid malignancies, and alpha-4-inegrin antagonists among others. This session will focus not only on mitigation of test interference, but on the rational for use of these therapies and biological consequences.
Review the development of immune therapy approaches and mechanisms of action.
Compare and contrast serologic reactivity seen when testing samples from patients receiving various monoclonal antibody therapies.
Discuss other potential targets that may be exploited in the future that are also present on RBCs and platelets.
Associate Director, Blood Bank and Transfusion Services,
University of Michigan